Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PMI vs NPCE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PMI Captures Overall Composite Edge (48.4 HOLD vs 48.8 HOLD), While NPCE Leads 4–1 on Growth & Valuation Pillars

PMI Overall Winner 6-Pillar Tally: PMI 1 – 4 NPCE (1 Tie) Matrix Metrics: PMI 6 – 4 NPCE

As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Neuropace, Inc. (NPCE) on higher Unified Composite conviction (48.4/100 HOLD vs. 48.8/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning), while NPCE wins 4–1 across the 6-pillar growth and valuation breakdown. PMI trades at $6.30 (N/M Forward P/E, -248.1% operating margin) versus NPCE at $8.14 (90.9x Forward P/E, -9.6% operating margin).

  • Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. NPCE 48.8/100 HOLD) and 54.06β · 134% Vol risk profile, whereas NPCE leads top-line expansion (-1.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PMI vs NPCE
PMI NYSE American Head-to-Head Winner
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62
NPCE NASDAQ
Neuropace, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$8.14
-0.97% 1D
Market Cap $283.2M
TTM Revenue $107M
Forward P/E 90.9x
Beta / 30D Vol 1.22β · 136% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 71.0 Mom 48.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 26
RSI-14: 26.3 · SMA20: $11.54 · SMA50: $12.70

6-Pillar Scorecard Institutional Category Breakdown (PMI 1 – 4 NPCE)

Columns: Metric · PMI · NPCE
1. Valuation Multiples NPCE
Forward P/E N/M 90.9x
Trailing P/E 2.9x 90.9x
PEG Ratio N/M N/M
EV / Revenue 3.2x 3.2x
2. Growth & Scale NPCE
Revenue Growth (YoY) +38.6% -1.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.3M $107M
Market Cap $17.1M $283.2M
3. Profitability & Quality NPCE
Gross Margin 18.6% 77.8%
Operating Margin -248.1% -9.6%
Net Profit Margin 0.0% -17.7%
Return on Equity (ROE) 0.0% -97.0%
4. Balance Sheet & Cash Flow NPCE
Cash Generation (TTM) -$17M -$12M
Cash Flow Margin N/A -10.9%
Net Cash / Leverage $3.2M Net Debt $57M Net Debt (5.88x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PMI
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 59.9% (10th %ile)
Put/Call OI Skew N/A 0.34x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PMI (6) vs NPCE (4)
Institutional Metric PMI NPCE Criterion Row Edge
Market Capitalization
Scale
$17.1M $283.2M Larger Scale NPCE
Trailing P/E Ratio
Valuation
2.9x 90.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M 90.9x Lower Multiple NPCE
Revenue Growth (YoY)
Growth
+38.6% -1.1% Higher Growth PMI
Operating Margin (TTM)
Profitability
-248.1% -9.6% Higher Margin NPCE
Net Profit Margin
Profitability
0.0% -17.7% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
0.0% -97.0% Higher ROE PMI
52-Week Range Position
Momentum
34% ($0–$18) 19% ($5–$20) Stronger Trend PMI
Beta / 30D Volatility
Risk Regime
54.06β · 134% Vol 1.22β · 136% Vol Lower Realized Risk PMI
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 48.8 / 100 (HOLD) Higher Composite NPCE
Trailing 12M Revenue (USD)
Operating Scale
$6.3M $107M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.6% 77.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($3.2M Net Debt) -$12M ($57M Net Debt (5.88x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PMI +3.04 pp
PMI: -34.58% · NPCE: -37.62%
3M Horizon PMI +138.24 pp
PMI: +96.26% · NPCE: -41.98%
6M Horizon PMI +3487.81 pp
PMI: +3439.33% · NPCE: -48.48%
1Y Horizon PMI +185.51 pp
PMI: +148.03% · NPCE: -37.48%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PMI Revenue NPCE Revenue PMI Op. Margin NPCE Op. Margin Margin Leader
FY2020 N/A $40M N/A -31.7% NPCE
FY2021 N/A $50M N/A -52.5% NPCE
FY2022 N/A $50M N/A -89.6% NPCE
FY2023 N/A $70M N/A -41.5% NPCE
FY2024 $0M $80M -312.3% -27.1% NPCE
FY2025 $0M $100M -268.4% -16.3% NPCE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NPCE BREAKDOWN
136d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 10th %ile
Put/Call OI Skew 0.34x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NPCE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NPCE Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $283.2M market capitalization and -9.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PMI vs NPCE Key Questions & Quantitative Answers

As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Neuropace, Inc. (NPCE) on higher Unified Composite conviction (48.4/100 HOLD vs. 48.8/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning), while NPCE wins 4–1 across the 6-pillar growth and valuation breakdown. PMI trades at $6.30 (N/M Forward P/E, -248.1% operating margin) versus NPCE at $8.14 (90.9x Forward P/E, -9.6% operating margin). Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. NPCE 48.8/100 HOLD) and 54.06β · 134% Vol risk profile, whereas NPCE leads top-line expansion (-1.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NPCE leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with NPCE at -1.1% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (77.8% gross margin, -9.6% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), PMI cumulative revenue shifted N/A while NPCE shifted +150.0%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NPCE.

NPCE screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas NPCE trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-10.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus NPCE (-97.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, NPCE carries 59.9% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.34x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 136% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.